Abstract

Postpartum depression can be treated, and most people who get proper care improve. Talking therapies and antidepressant medicines are the main options, and health services ask people to tell their doctor if they are breastfeeding. Two newer medicines that act on a brain signalling system have been studied for postpartum depression, although the trials behind them were short. Postpartum psychosis is a rare but serious medical emergency that calls for immediate medical help. Counselling can help prevent depression in people at higher risk, while several questions about medicines after birth are still uncertain.

Keywords: postpartum depression, talking therapies, antidepressants, postpartum psychosis, perinatal depression

Get Help Now

Anyone who is thinking about suicide or self-harm, or who feels unable to cope, should contact a crisis line straight away. People in immediate danger should call their local emergency number.

- United States: the 988 Suicide & Crisis Lifeline takes calls and texts at 988 (988lifeline.org). - United Kingdom: Samaritans can be called free on 116 123 (samaritans.org). - Canada: the Suicide Crisis Helpline takes calls and texts at 9-8-8 (988.ca). - Australia: Lifeline can be called on 13 11 14 (lifeline.org.au).

Postpartum psychosis, a rare but serious illness after birth, is a medical emergency. This guide describes what published clinical guidelines and research reviews say about treating postpartum depression. It is not a substitute for advice from a doctor, midwife or other health professional who knows a person's situation.

How Treatment Is Chosen

The National Health Service (NHS) in the United Kingdom says postnatal depression, another name for postpartum depression, can be treated (National Health Service, 2026). It notes that the illness usually gets better, and that recovery is more likely with treatment than without (National Health Service, 2026). The NHS lists talking therapies and antidepressants as the main forms of depression treatment after birth (National Health Service, 2026). The National Institute of Mental Health (NIMH) in the United States also says perinatal depression is treatable (National Institute of Mental Health, 2023). NIMH describes three paths: therapy, medicine, or both together (National Institute of Mental Health, 2023). It adds that most women improve with proper treatment (National Institute of Mental Health, 2023).

The American College of Obstetricians and Gynecologists (ACOG) in the United States has a clinical guideline on psychiatric medicines for pregnant and postpartum people (American College of Obstetricians and Gynecologists, 2023). It covers depression, anxiety, bipolar disorder and acute postpartum psychosis (American College of Obstetricians and Gynecologists, 2023). A review of pregnancy studies concluded that the small differences linked to antidepressants are something to weigh against the risks of untreated depression (Ross et al., 2013).

Talking Therapies

NIMH lists psychotherapy, or talking therapy, among the main treatments, and it names cognitive behavioural therapy (CBT) and interpersonal therapy (IPT) (National Institute of Mental Health, 2023).

A 2023 meta-analysis combined 43 randomised trials with 6,270 participants (Cuijpers et al., 2023). Psychological treatment worked better than control conditions for perinatal depression, with a moderate to large effect of g = 0.67 (Cuijpers et al., 2023). The authors judged these treatments probably effective, with benefits lasting 6 to 12 months (Cuijpers et al., 2023). At 13 to 24 months, the effect was no longer significant (Cuijpers et al., 2023). The review found no significant difference in effect between types of therapy, or between studies during pregnancy and after birth (Cuijpers et al., 2023). Results varied widely between studies, and there were signs of some publication bias (Cuijpers et al., 2023). After adjusting for that bias, the effect was g = 0.53 (Cuijpers et al., 2023).

IPT was the focus of a 2018 review of 28 studies covering pregnancy and the first year after birth (Sockol, 2018). In treatment studies, IPT lowered depression and anxiety and improved relationship quality and social support (Sockol, 2018). Used for prevention, it reduced depressive symptoms (Sockol, 2018). The review cautioned that too few studies were available to compare subgroups well (Sockol, 2018).

Medicines and Breastfeeding

A 2021 Cochrane review pooled 11 trials with 1,016 women who had postnatal depression (Brown et al., 2021). It found that SSRIs, a common class of antidepressant, may work better than a placebo, or dummy pill (Brown et al., 2021). About 55% of women on SSRIs responded to treatment, compared with 43% on placebo (Brown et al., 2021). About 42% reached remission, meaning their symptoms largely cleared, compared with 27% on placebo (Brown et al., 2021). Certainty was low, and the range of likely results for both measures included no real difference (Brown et al., 2021). Many women had side effects, but no study found evidence of a difference in their number between groups, and the authors could not pool the side effect data (Brown et al., 2021).

NIMH notes that antidepressants can take 4 to 8 weeks to work, and some people may try several medicines (National Institute of Mental Health, 2023). It also notes that all medicines can have side effects, and that in some cases people under 25 may have more suicidal thoughts or behaviour when taking antidepressants, especially in the first few weeks (National Institute of Mental Health, 2023). NIMH advises people to tell their provider if they are pregnant or nursing (National Institute of Mental Health, 2023). The NHS likewise advises telling the doctor about breastfeeding (National Health Service, 2026).

Some people took antidepressants while pregnant, and a 2013 review of 23 studies looked at their birth outcomes (Ross et al., 2013). Exposure was linked to earlier delivery, lower birth weight and lower Apgar scores, a quick check of a newborn's health (Ross et al., 2013). Miscarriage was not significantly more common (Ross et al., 2013). The authors judged the differences small and mostly within the normal range (Ross et al., 2013). NIMH says the risk of birth defects is very low (National Institute of Mental Health, 2023).

Newer Medicines

Brexanolone was first approved in mid-March 2019, in the USA, as a treatment for postpartum depression in adult women (Scott, 2019). It is a neuroactive steroid, a steroid compound that acts on the brain's GABA A receptor (Scott, 2019). Zuranolone was first approved in August 2023, in the USA, as a treatment for adults with postpartum depression (Heo, 2023). At that time, its scheduling by the Drug Enforcement Administration (DEA) was still pending (Heo, 2023).

A review by authors linked to the maker of brexanolone tied GABA signalling and a brain steroid called allopregnanolone to postpartum depression (Meltzer-Brody & Kanes, 2020). They called this route promising, while noting that the exact cause of the illness is unknown (Meltzer-Brody & Kanes, 2020). Sedation, or heavy sleepiness, severe enough to pause or lower the dose during the infusion occurred in 5% of people given brexanolone and in none on placebo (Meltzer-Brody & Kanes, 2020). Because of sedation and loss of consciousness, its use is restricted under a safety programme (Meltzer-Brody & Kanes, 2020). NIMH notes that in clinical trials, zuranolone eased severe postpartum depression faster than traditional antidepressants did (National Institute of Mental Health, 2023).

A 2025 Cochrane review covered 6 trials with 674 women, all in the United States (Wilson et al., 2025). Zuranolone beat placebo for response and remission, with moderate certainty, but it caused more side effects for mothers (Wilson et al., 2025). Brexanolone given into a vein may make little or no difference to depression symptoms compared with placebo, with low certainty (Wilson et al., 2025). Every trial was funded by industry, none compared these medicines with other treatments, and follow-up lasted at most 45 days (Wilson et al., 2025).

Severe Illness After Birth

The NHS describes postpartum psychosis as a rare, severe illness and a medical emergency (National Health Service, 2023). It affects around 1 in 1,000 mothers and tends to begin in the first 2 weeks after giving birth (National Health Service, 2023). Signs on the NHS page include hallucinations, which means seeing, hearing or feeling things that are not there, and delusions, which are fears or beliefs that are unlikely to be true (National Health Service, 2023). Other signs include confusion, low mood, restlessness, and mania, a very high and overactive mood (National Health Service, 2023). Symptoms can start suddenly and worsen fast, and the person may not realise they are ill (National Health Service, 2023). The NHS advises seeing a GP (family doctor) immediately and asking for an urgent assessment that day, and calling 999 or going to A&E if anyone may be in danger of imminent harm (National Health Service, 2023). The NHS says most people make a full recovery if they get the right treatment and support, and that full recovery can take 6 to 12 months or more (National Health Service, 2023).

A 2015 systematic review looked at electroconvulsive therapy (ECT), a hospital treatment that uses brief electrical stimulation of the brain, after birth (Gressier et al., 2015). It found 8 studies and 8 case reports, and every study reported that ECT worked (Gressier et al., 2015). They also noted that little is known about ECT in this period (Gressier et al., 2015).

Preventing Postpartum Depression

The United States Preventive Services Task Force (USPSTF) recommends counselling for pregnant and postpartum women at increased risk of perinatal depression (Krist et al., 2019). It gave this a B recommendation, based on moderate certainty of a moderate net benefit (Krist et al., 2019). Risk factors it names include a history of depression, current depressive symptoms, low income, and being a young or single parent (Krist et al., 2019). The counselling it reviewed included CBT and IPT, and the harms were judged no greater than small (Krist et al., 2019). For other kinds of prevention, the evidence was not enough to judge (Krist et al., 2019).

A 2013 Cochrane review of trials with almost 17,000 women found that psychosocial and psychological support lowered the risk of postpartum depression (Dennis & Dowswell, 2013). Support from health professionals and from trained lay people both helped (Dennis & Dowswell, 2013).

Whether antidepressants can prevent postnatal depression is unproven (Molyneaux et al., 2018). A 2018 Cochrane review found only 2 small trials, with 81 women who had had postnatal depression before (Molyneaux et al., 2018). The evidence was of very low quality, so the authors could draw no clear conclusions (Molyneaux et al., 2018).

Effects on the Baby and Family

A 2017 review of 36 trials asked whether treating a mother's depression during pregnancy or after birth also helps parenting and children (Letourneau et al., 2017). For depression after birth, guidance on mother and baby interaction and psychotherapeutic group support showed large benefits for parenting and child development (Letourneau et al., 2017). Pooled results found no significant effect of IPT on attachment, the bond between parent and baby, or of CBT on parenting stress (Letourneau et al., 2017). The authors called the results promising for specific outcomes and asked for more trials with shared measures (Letourneau et al., 2017).

A 2015 meta-analysis of nine studies found that therapy lowered depression in mothers (g = 0.66) (Cuijpers et al., 2015). It also pointed to gains in children's mental health (g = 0.40) and in mother and child interaction (g = 0.35) (Cuijpers et al., 2015). The authors noted that study quality was not ideal and that the measures varied a great deal (Cuijpers et al., 2015).

What Is Still Uncertain

Evidence on antidepressants after birth is limited. The 2021 Cochrane review rated its findings low or very low in certainty, drawn from few studies with many dropouts (Brown et al., 2021). It had little data on severe depression or on children and parenting, and most trials came from high-income, English-speaking countries (Brown et al., 2021). For the newer medicines, the trials in the 2025 review reported no results beyond 45 days after treatment began, and none measured quality of life (Wilson et al., 2025). Its authors warned that their conclusions may change as more studies appear (Wilson et al., 2025). NIMH notes that researchers are still studying treatment options (National Institute of Mental Health, 2023).

Pregnancy studies face a different problem: separating the medicine from the illness. When the 2013 review compared exposed babies with babies of depressed mothers who took no antidepressant, the birth weight difference was no longer significant (Ross et al., 2013). Differences in preterm birth, length of pregnancy and Apgar scores remained, but they were small (Ross et al., 2013). The authors said the clinical meaning of these differences calls for careful weighing, and they included only English-language studies (Ross et al., 2013). For talking therapies, the 2023 meta-analysis of 43 trials judged psychological treatment probably effective, though it urged caution because results varied widely between studies (Cuijpers et al., 2023).

Learn More

More detail is in the full article on postpartum depression and the guide to depression treatment. There is also a guide to postpartum depression symptoms.

Frequently Asked Questions

Can postpartum depression be treated?

Yes. The NHS says postnatal depression usually gets better, and that recovery is more likely with treatment than without it (National Health Service, 2026).

Do talking therapies work for depression after birth?

A 2023 meta-analysis of 43 trials found that psychological treatment probably works, with a moderate to large effect (Cuijpers et al., 2023). The benefit was still significant at 6 to 12 months; in the four studies that looked at 13 to 24 months, it was not significant (Cuijpers et al., 2023).

What happens with antidepressants during breastfeeding?

The NHS advises anyone being treated for postnatal depression to tell their doctor if they are breastfeeding (National Health Service, 2026).

How long do antidepressants take to work?

NIMH notes that antidepressants usually take 4 to 8 weeks to work, and that in clinical trials zuranolone eased severe postpartum depression faster than traditional antidepressants did (National Institute of Mental Health, 2023).

What is postpartum psychosis?

The NHS describes it as a rare, severe illness and a medical emergency, affecting around 1 in 1,000 mothers (National Health Service, 2023). The NHS advises seeing a GP (family doctor) immediately for an urgent assessment that day, or calling 999 if anyone may be in danger of imminent harm (National Health Service, 2023).

Can postpartum depression be prevented?

The USPSTF recommends counselling for pregnant and postpartum women at increased risk, based on moderate certainty of a moderate net benefit (Krist et al., 2019).

How This Article Was Prepared

This is a plain-language patient guide, not a systematic review. Following medical sourcing guidance, it rests on secondary sources rather than single studies: two clinical guidelines, 13 reviews of the research and three pages from public health agencies.

- Included: 18 sources, each confirmed against the publisher's or indexer's own record. Six read in full text and 12 from their abstracts. Agency and guideline pages were read on the publisher's own site. Abstracts came from PubMed and Crossref. - Identifiers: 15 references carry a PubMed ID and six a PubMed Central ID, each confirmed by the National Library of Medicine against the cited DOI. - Retractions: 15 sources were checked for retractions and editorial notices; none was retracted. - Publication dates: nine from the 2010s and nine from 2020 or later. - Checked against sources: each of the 93 cited sentences was matched to a passage in its source, and an independent reviewer checked the article against those sources over three passes before publication. - Limits: a short guide summarises selected sources and cannot cover every symptom or situation; it is not a diagnosis or a substitute for seeing a health professional. Each sentence was accepted only after its cited source had been searched for contrary evidence.

See our Editorial Policy for the full method.

References

American College of Obstetricians and Gynecologists. (2023). Treatment and management of mental health conditions during pregnancy and postpartum: ACOG Clinical Practice Guideline No. 5. Obstetrics & Gynecology, 141(6), 1262-1288. https://doi.org/10.1097/AOG.0000000000005202 PMID: 37486661

Brown, J. V. E., Wilson, C. A., Ayre, K., Robertson, L., South, E., Molyneaux, E., Trevillion, K., Howard, L. M., & Khalifeh, H. (2021). Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews, 2021(2), CD013560. https://doi.org/10.1002/14651858.CD013560.pub2 PMID: 33580709 · PMCID: PMC8094614

Cuijpers, P., Franco, P., Ciharova, M., Miguel, C., Segre, L., Quero, S., & Karyotaki, E. (2023). Psychological treatment of perinatal depression: a meta-analysis. Psychological Medicine, 53(6), 2596-2608. https://doi.org/10.1017/S0033291721004529 PMID: 37310303 · PMCID: PMC10123831

Cuijpers, P., Weitz, E., Karyotaki, E., Garber, J., & Andersson, G. (2015). The effects of psychological treatment of maternal depression on children and parental functioning: a meta-analysis. European Child & Adolescent Psychiatry, 24(2), 237-245. https://doi.org/10.1007/s00787-014-0660-6 PMID: 25522839

Dennis, C.-L., & Dowswell, T. (2013). Psychosocial and psychological interventions for preventing postpartum depression. Cochrane Database of Systematic Reviews, (2), CD001134. https://doi.org/10.1002/14651858.CD001134.pub3 PMID: 23450532 · PMCID: PMC11936315

Gressier, F., Rotenberg, S., Cazas, O., & Hardy, P. (2015). Postpartum electroconvulsive therapy: A systematic review and case report. General Hospital Psychiatry, 37(4), 310-314. https://doi.org/10.1016/j.genhosppsych.2015.04.009 PMID: 25929986

Heo, Y.-A. (2023). Zuranolone: First approval. Drugs, 83(16), 1559-1567. https://doi.org/10.1007/s40265-023-01953-x PMID: 37882942

Letourneau, N. L., Dennis, C.-L., Cosic, N., & Linder, J. (2017). The effect of perinatal depression treatment for mothers on parenting and child development: A systematic review. Depression and Anxiety, 34(10), 928-966. https://doi.org/10.1002/da.22687 PMID: 28962068

Meltzer-Brody, S., & Kanes, S. J. (2020). Allopregnanolone in postpartum depression: Role in pathophysiology and treatment. Neurobiology of Stress, 12, 100212. https://doi.org/10.1016/j.ynstr.2020.100212 PMID: 32435663 · PMCID: PMC7231991

Molyneaux, E., Telesia, L. A., Henshaw, C., Boath, E., Bradley, E., & Howard, L. M. (2018). Antidepressants for preventing postnatal depression. Cochrane Database of Systematic Reviews, (4), CD004363. https://doi.org/10.1002/14651858.cd004363.pub3 PMID: 29669175 · PMCID: PMC6494522

National Health Service. (2026, March 18). Postnatal depression. NHS. https://www.nhs.uk/mental-health/conditions/postnatal-depression/

National Health Service. (2023, October 18). Postpartum psychosis. NHS. https://www.nhs.uk/mental-health/conditions/post-partum-psychosis/

National Institute of Mental Health. (2023). Perinatal depression (NIH Publication No. 23-MH-8116). U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/publications/perinatal-depression

Ross, L. E., Grigoriadis, S., Mamisashvili, L., Vonderporten, E. H., Roerecke, M., Rehm, J., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., & Cheung, A. (2013). Selected pregnancy and delivery outcomes after exposure to antidepressant medication: A systematic review and meta-analysis. JAMA Psychiatry, 70(4), 436-443. https://doi.org/10.1001/jamapsychiatry.2013.684 PMID: 23446732

Scott, L. J. (2019). Brexanolone: First global approval. Drugs, 79(7), 779-783. https://doi.org/10.1007/s40265-019-01121-0 PMID: 31006078

Sockol, L. E. (2018). A systematic review and meta-analysis of interpersonal psychotherapy for perinatal women. Journal of Affective Disorders, 232, 316-328. https://doi.org/10.1016/j.jad.2018.01.018 PMID: 29501991

US Preventive Services Task Force; Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Jr., Grossman, D. C., Kemper, A. R., Kubik, M., Landefeld, C. S., Mangione, C. M., Silverstein, M., Simon, M. A., Tseng, C.-W., & Wong, J. B. (2019). Interventions to prevent perinatal depression: US Preventive Services Task Force recommendation statement. JAMA, 321(6), 580-587. https://doi.org/10.1001/jama.2019.0007 PMID: 30747971

Wilson, C. A., Robertson, L., Ayre, K., Hendon, J. L., Dawson, S., Bridges, C., & Khalifeh, H. (2025). Brexanolone, zuranolone and related neurosteroid GABAA receptor positive allosteric modulators for postnatal depression. Cochrane Database of Systematic Reviews, 2025(6), CD014624. https://doi.org/10.1002/14651858.cd014624.pub2 PMID: 40562419 · PMCID: PMC12197409